Campbell & CO Investment Adviser LLC Biomarin Pharmaceutical Inc Transaction History

Campbell & CO Investment Adviser LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $1.41 Million - $1.75 Million	-18,924 Reduced 58.93%	13,186 $1.09 Million
Q1 2024 May 10, 2024	BUY	$83.81 - $99.0 $2.39 Million - $2.83 Million	28,556 Added 803.49%	32,110 $2.8 Million
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $270,885 - $350,104	3,554 New	3,554 $342,000
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $291,678 - $337,509	3,365 New	3,365 $291,000
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $643,798 - $864,151	7,955 Added 178.76%	12,405 $1.28 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $597,714 - $705,238	-7,275 Reduced 62.05%	4,450 $377,000
Q2 2022 Aug 09, 2022	BUY	$71.48 - $86.85 $838,103 - $1.02 Million	11,725 New	11,725 $972,000
Q1 2022 May 09, 2022	SELL	$74.28 - $92.69 $441,966 - $551,505	-5,950 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $426,734 - $544,246	5,950 New	5,950 $526,000
Q2 2019 Jul 10, 2019	SELL	$80.35 - $93.9 $857,414 - $1 Million	-10,671 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$84.2 - $98.62 $898,498 - $1.05 Million	10,671 New	10,671 $948,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.